Joshua Brumm is the founder of Dyne Therapeutics. Dyne Therapeutics has raised $200M in total funding. Latest round: Series E.
Joshua Brumm is the President and Chief Executive Officer of Dyne Therapeutics, a biotechnology company founded in 2018. The company is focused on pioneering targeted therapies for patients with serious muscle diseases, utilizing its FORCE therapeutic platform. Dyne Therapeutics is developing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). Prior to joining Dyne, Mr. Brumm served as COO and CFO at Kaleido Biosciences and Versartis, leading multiple financings and IPOs.
Full founder directory · Investor directory · Company funding database · Fundraising library